Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Weiß, Thomas; Henderson, Scott C.; McHorney, Colleen A.; Cramer, Joyce A.

doi:10.1185/030079907x226069

Cited by 42 publications

(26 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consensus on improved compliance with weekly over daily dosing is well documented [10], but prior findings regarding weekly versus monthly dosing are not consistent. Using administrative claims data, both Briesacher [12] and Weiss [16] found no significant difference in bisphosphonate compliance or persistence among new users initiating with weekly versus monthly dosing. Briesacher reported a 49% compliance rate for both dosing cohorts (based on a MPR ≥80%), but found a modest improvement in adherence with prior bone mineral density (BMD) testing and reduced compliance with increasing comorbidity index [12].…”

Section: Discussionmentioning

confidence: 99%

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

Devine¹,

Trice²,

Finney³

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

Devine¹,

Trice²,

Finney³

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

“…However, the study was performed soon after the initial release of ibandronate and results are biased by the refilling gap of 30 days that disadvantaged the monthly regimen and by the co-payment variation in the US healthcare system, with many patients initiating monthly therapy for free with a voucher and not refilling the first box. There was also no information about free samples directly distributed by GPs (23). Several other determinants of therapeutic adherence have been reported, such as hospitalization for osteoporosis (24), an initial prescription by a rheumatologist (24), patient motivation (25,26), and the onset of bothersome side effects (2).…”

Section: Discussionmentioning

confidence: 99%

Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database

Confavreux

Canouï‐Poitrine²,

Schott³

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Treatments against osteoporosis have demonstrated fracture risk reduction but persistence to therapy remains a major issue. Intermittent regimens have been developed to improve persistence. The aim of this 1-year prospective study was to compare, in the general population, the persistence of various oral regimens of antiosteoporotic treatment. Methods: We conducted this prospective study in the French comprehensive public health insurance database of the Rhône-Alpes region. Women aged 45 years or older who had a first reimbursement of an oral antiosteoporotic treatment during February 2007 composed the study cohort. Persistence was defined by the proportion of patients refilling a prescription in the pharmacist delivery register (ERASME). Using statistical analyses like Kaplan-Meier survival curves and log-rank tests, we compared the treatment persistence of strontium ranelate, raloxifene, and daily-, weekly-, and monthly bisphosphonates. Results: Two thousand four hundred and nineteen patients were included over a period of 1 month and followed up for 12 months. Two hundred and eighty-nine (11.9%) patients were treated with monthly bisphosphonates, 1298 (53.7%) with weekly bisphosphonates, and 832 (34.4%) with daily treatments (526 strontium ranelate (21.7%), 296 raloxifene (12.2%), and 10 bisphosphonates (0.4%)). At 1 year, overall persistence was 34%. Fifty percent of patients on monthly bisphosphonates were still persistent while only 37% of patients on weekly bisphosphonates, 34% on raloxifene, and 16% on strontium ranelate were persistent. Therapy monitoring with biochemical markers or bone mineral density was associated with improved persistence. Conclusion: Overall persistence at 1 year was low, but intermittent regimens were associated with higher persistence rates, along with women who had therapy monitoring.

show abstract

“…Other persistence database studies comparing monthly and weekly bisphosphonate regimens have been completed. 64,65 However, it is likely that differences in methodology, such as a lack of adjustment for confounding variables and not tailoring the refill gap for individual regimen dosing windows, have led to varying results from those summarized above. 61 To further characterize the reported improved adherence with monthly versus weekly bisphosphonate regimens an open-label study (PRIOR) enrolled patients (n = 543) who had discontinued daily or weekly alendronate or risedronate due to perceived or actual GI intolerance.…”

Section: Patient Preferencementioning

confidence: 94%

Ibandronate in the Management of Postmenopausal Osteoporosis

Reginster

Hiligsmann

Rabenda

et al. 2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Ibandronate is a potent, nitrogen-containing bisphosphonate which, uniquely, can be administered either orally, monthly, or as an intravenous injection, every 3 months. A positive impact for adherence has been observed with a reduction in the bisphosphonate dosing frequency. Anti-fracture efficacy of the various currently available regimens of ibandronate is documented in randomized controlled clinical trials, non-inferiority studies, meta-analyses and real-life settings studies. The present paper summarizes the pharmacology, efficacy and tolerability of oral and intravenous ibandronate, when administered with extended dosing intervals, in postmenopausal osteoporosis.

show abstract

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Abstract: Monthly dosing does not appear to be associated with improvements in patient persistence with oral bisphosphonates for patients newly initiated on bisphosphonates.

Cited by 42 publications

References 57 publications

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database

Ibandronate in the Management of Postmenopausal Osteoporosis

Contact Info

Product

Resources

About